

# Christian Pagnoux

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/616363/publications.pdf>

Version: 2024-02-01

166  
papers

11,264  
citations

61984

43  
h-index

30087

103  
g-index

169  
all docs

169  
docs citations

169  
times ranked

5857  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vision loss in granulomatosis with polyangiitis: when prednisone is the problem, not the solution. <i>Clinical Rheumatology</i> , 2022, 41, 943-944.	2.2	1
2	Updates in ANCA-associated vasculitis. , 2022, 9, 153-166.		8
3	Cessation of immunosuppressive therapies in patients with Takayasu arteritis with sustained inactive disease. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151934.	3.4	2
4	Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry. <i>RMD Open</i> , 2022, 8, e002160.	3.8	9
5	Paediatric-to-adult transition experience in vasculitis: report of a model of care and outcomes.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
6	An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152021.	3.4	2
7	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. <i>Interactive Journal of Medical Research</i> , 2022, 11, e27273.	1.4	2
8	Pregnancy outcomes in women with primary systemic vasculitis: a retrospective study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2021, 34, 1-7.	1.5	15
9	Sustained Remission of Granulomatosis With Polyangiitis After Discontinuation of Glucocorticoids and Immunosuppressant Therapy: Data From the French Vasculitis Study Group Registry. <i>Arthritis and Rheumatology</i> , 2021, 73, 641-650.	5.6	8
10	CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update. <i>Journal of Rheumatology</i> , 2021, 48, 555-566.	2.0	27
11	Granulomatosis with polyangiitis presenting as pancreatic disease. <i>BMJ Case Reports</i> , 2021, 14, e241033.	0.5	2
12	Pulmonary involvement in primary systemic vasculitides. <i>Rheumatology</i> , 2021, 61, 319-330.	1.9	16
13	Granulomatosis with polyangiitis: Study of 795 patients from the French Vasculitis Study Group registry. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 339-346.	3.4	22
14	Update on Maintenance Therapies for ANCA-Associated Vasculitis. <i>Current Treatment Options in Rheumatology</i> , 2021, 7, 112.	1.4	0
15	Update in the Management of ANCA-Associated Vasculitis: Recent Developments and Future Perspectives. <i>International Journal of Rheumatology</i> , 2021, 2021, 1-14.	1.6	10
16	Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , 2021, 3, 404-412.	2.1	21
17	Avacopan for the treatment of ANCA-associated vasculitis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 717-726.	3.0	10
18	Comparison of Two Rituximab Induction Regimens for Antineutrophil Cytoplasm Antibody-Associated Vasculitis: Systematic Review and Meta-Analysis. <i>ACR Open Rheumatology</i> , 2021, 3, 484-494.	2.1	17

#	ARTICLE	IF	CITATIONS
19	Significance of eosinophilia in granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry. <i>Rheumatology</i> , 2021, , .	1.9	4
20	Facteurs prédictifs d'événements cardiovasculaires mortels et non mortels dans la vascularite à ANCA: données de la cohorte Toronto CanVasc. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 279-283.	0.0	0
21	Use of Rituximab for the Treatment of Antineutrophil Cytoplasm Antibody-associated Vasculitis in Canada, 2010-2020. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.210537.	2.0	0
22	ANCA status and renal parameters at month 12 post-diagnosis can help predict subsequent relapses in patients with granulomatosis with polyangiitis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1011-1015.	3.4	3
23	Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1134-1138.	3.4	4
24	Patients of 75 years and over with ANCA-associated vasculitis have a lower relapse risk than younger patients: A multicentre cohort study. <i>Journal of Internal Medicine</i> , 2021, , .	6.0	8
25	A Tale of 2 Aneurysms. <i>JACC: Case Reports</i> , 2021, 3, 1858-1862.	0.6	0
26	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 114-118.	0.8	3
27	Assessment of glucocorticoid tapering in large vessel and anti-neutrophil cytoplasmic antibody-associated vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 119-124.	0.8	1
28	Assessment of glucocorticoid tapering in large vessel and anti-neutrophil cytoplasmic antibody-associated vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 119-124.	0.8	2
29	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 114-118.	0.8	14
30	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 1001-1010.	2.0	20
31	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020, 72, 1615-1624.	3.4	77
32	Management of cutaneous vasculitis. <i>Presse Medicale</i> , 2020, 49, 104033.	1.9	20
33	Impact of diabetes, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use, and statin use on presentation and outcomes in patients with giant cell arteritis. <i>International Journal of Rheumatic Diseases</i> , 2020, 23, 1233-1239.	1.9	9
34	Editorial. <i>Presse Medicale</i> , 2020, 49, 104040.	1.9	0
35	Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>ACR Open Rheumatology</i> , 2020, 2, 662-671.	2.1	64
36	Long-term use and remission of granulomatosis with polyangiitis with the oral C5a receptor inhibitor avacopan. <i>BMJ Case Reports</i> , 2020, 13, e236236.	0.5	11

#	ARTICLE	IF	CITATIONS
37	Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1314-1325.	3.4	17
38	Pregnancy Outcomes in Systemic Vasculitides. <i>Current Rheumatology Reports</i> , 2020, 22, 63.	4.7	20
39	Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone. <i>Trials</i> , 2020, 21, 362.	1.6	14
40	Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1243-1249.	0.9	93
41	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2020, 382, 622-631.	27.0	465
42	Predictors of fatal and non-fatal cardiovascular events in ANCA-associated vasculitis: Data from the Toronto CanVasc cohort. <i>Joint Bone Spine</i> , 2020, 87, 221-224.	1.6	12
43	Characteristics of Takayasu Arteritis Patients with Severe Ischemic Events. <i>Journal of Rheumatology</i> , 2020, 47, 1224-1228.	2.0	6
44	Patterns of clinical presentation in Takayasu's arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 576-581.	3.4	25
45	Granulomatosis with Polyangiitis. <i>Rare Diseases of the Immune System</i> , 2020, , 97-129.	0.1	1
46	Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a Canadian single-centre cohort. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 171-175.	0.8	1
47	Presentation and Disease Course of Childhood Onset Versus Adult Onset Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 315-323.	5.6	38
48	Treatment of systemic necrotizing vasculitides: recent advances and important clinical considerations. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 939-949.	3.0	4
49	Prevalence and management of cardiovascular risk factors in ANCA-associated vasculitis. <i>Rheumatology</i> , 2019, 58, 2333-2335.	1.9	14
50	Hidradenitis suppurativa and vasculitis: A case series and literature review of a rare association. <i>SAGE Open Medical Case Reports</i> , 2019, 7, 2050313X1988285.	0.3	4
51	238. Efficacy of Conventional Immunosuppressants in Steroid-Dependent or Refractory Eosinophilic Granulomatosis with Polyangiitis: Study on a New Canadian Patient Cohort. <i>Rheumatology</i> , 2019, 58, .	1.9	1
52	355. Factors Predicting Severe Infections in Patients with Systemic Necrotizing Vasculitides Based on Data from 733 Patients Enrolled in Randomized Controlled Trials. <i>Rheumatology</i> , 2019, 58, .	1.9	1
53	330. Treatment Response Criteria for ANCA-Associated Vasculitis: Results of a Scoping Review. <i>Rheumatology</i> , 2019, 58, .	1.9	0
54	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019, 58, 2203-2211.	1.9	37

#	ARTICLE	IF	CITATIONS
55	Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Expert Opinion on Biological Therapy, 2019, 19, 617-630.	3.1	14
56	148.â€fSHORT-FORM 36 AS A MEASURE OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH GIANT CELL ARTERITIS. Rheumatology, 2019, 58, .	1.9	0
57	045.â€fEVALUATION OF NOVEL SERUM BIOMARKERS OF DISEASE ACTIVITY IN GIANT CELL ARTERITIS, TAKAYASUâ€™S ARTERITIS, POLYARTERITIS NODOSA, AND EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS. Rheumatology, 2019, 58, .	1.9	0
58	Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial. Rheumatology, 2019, 58, 2107-2116.	1.9	33
59	020.â€fIDENTIFICATION OF TARGET ANTIGENS FOR ANTI-ENDOTHELIAL CELL ANTIBODIES IN PATIENTS WITH TAKAYASUâ€™S ARTERITIS USING PROTEOMICS. Rheumatology, 2019, 58, .	1.9	0
60	043.â€fSUBGLOTTIC STENOSIS AND ENDOBRONCHIAL DISEASE IN GRANULOMATOSIS WITH POLYANGIITIS. Rheumatology, 2019, 58, .	1.9	0
61	035.â€fCANDIDATE BIOMARKERS IN ANCA-ASSOCIATED VASCULITIS IDENTIFIED USING A PROTEOMIC APPROACH. Rheumatology, 2019, 58, .	1.9	0
62	084.â€fDISCOVERY AND VALIDATION OF A NOVEL ANGIOGRAPHIC CLASSIFICATION SCHEME IN TAKAYASUâ€™S ARTERITIS. Rheumatology, 2019, 58, .	1.9	0
63	138.â€fDIFFUSE ALVEOLAR HEMORRHAGE, PULMONARY NODULES AND INFILTRATES IN GRANULOMATOSIS POLYANGIITIS AND MICROSCOPIC POLYANGIITIS. A COHORT STUDY OF 736 PATIENTS. Rheumatology, 2019, 58, .	1.9	0
64	083.â€fCOMPARISON OF ARTERIAL PATTERNS OF DISEASE IN TAKAYASUâ€™S ARTERITIS AND GIANT CELL ARTERITIS. Rheumatology, 2019, 58, .	1.9	3
65	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. Journal of Rheumatology, 2019, 46, 928-934.	2.0	6
66	Advances in the diagnosis of giant cell arteritis. Current Opinion in Ophthalmology, 2019, 30, 407-411.	2.9	5
67	Emergence of severe spondyloarthropathy-related enthesal pathology following successful vedolizumab therapy for inflammatory bowel disease. Rheumatology, 2019, 58, 963-968.	1.9	42
68	Diagnosis and management of <sc>ADA</sc>2 deficient polyarteritis nodosa. International Journal of Rheumatic Diseases, 2019, 22, 69-77.	1.9	28
69	Infectionâ€-associated vasculitides. International Journal of Rheumatic Diseases, 2019, 22, 109-115.	1.9	15
70	Microscopic polyangiitis and granulomatosis with polyangiitis. , 2019, , 153-172.		1
71	Comments on the giant cell arteritis probability score. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 150.	0.8	0
72	Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides. Annals of the Rheumatic Diseases, 2018, 77, 1150-1156.	0.9	139

#	ARTICLE	IF	CITATIONS
73	Non-glucocorticoid drugs for the treatment of Takayasu's arteritis: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2018, 17, 683-693.	5.8	50
74	Patient Outcomes in Renal-Limited Antineutrophil Cytoplasmic Antibody Vasculitis With Inactive Histology. <i>Kidney International Reports</i> , 2018, 3, 671-676.	0.8	5
75	Prognostic Significance of Cavitory Lung Nodules in Granulomatosis With Polyangiitis (Wegener's): A Clinical Imaging Study of 225 Patients. <i>Arthritis Care and Research</i> , 2018, 70, 1082-1089.	3.4	12
76	Reply. <i>Arthritis and Rheumatology</i> , 2018, 70, 151-152.	5.6	1
77	Childhood- versus adult-onset ANCA-associated vasculitides: A nested, matched caseâ€“control study from the French Vasculitis Study Group Registry. <i>Autoimmunity Reviews</i> , 2018, 17, 108-114.	5.8	42
78	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. <i>PLoS ONE</i> , 2018, 13, e0205768.	2.5	6
79	Long-term outcomes of patients with Takayasu arteritis and renal artery involvement: a cohort study. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky026.	0.7	11
80	Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. <i>Kidney International Reports</i> , 2018, 3, 1039-1049.	0.8	41
81	Mortality in systemic necrotizing vasculitides: A retrospective analysis of the French Vasculitis Study Group registry. <i>Autoimmunity Reviews</i> , 2018, 17, 653-659.	5.8	40
82	Conventional and biological immunosuppressants in vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 94-111.	3.3	9
83	Impact of vasculitis on employment and income. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 58-64.	0.8	4
84	A Randomized, Doubleâ€“Blind Trial of Abatacept (CTLAâ€“4Ig) for the Treatment of Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 846-853.	5.6	131
85	A Randomized, Doubleâ€“Blind Trial of Abatacept (CTLAâ€“4Ig) for the Treatment of Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 837-845.	5.6	271
86	ActualitÃ©s thÃ©rapeutiques de la granulomatose avec polyangÃ©ite (Wegener) et de la polyangÃ©ite microscopique. <i>Revue Du Rhumatisme Monographies</i> , 2017, 84, 242-248.	0.0	4
87	Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1662-1668.	0.9	159
88	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibodyâ€“Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1054-1066.	5.6	130
89	Adding Azathioprine to Remissionâ€“Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churgâ€“Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors. <i>Arthritis and Rheumatology</i> , 2017, 69, 2175-2186.	5.6	117
90	Concordance of Time-of-Flight MRA and Digital Subtraction Angiography in Adult Primary Central Nervous System Vasculitis. <i>American Journal of Neuroradiology</i> , 2017, 38, 1917-1922.	2.4	17

#	ARTICLE	IF	CITATIONS
91	Investigational drugs in systemic vasculitis. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1049-1061.	4.1	5
92	High-Resolution Magnetic Resonance Imaging of Scalp Arteries for the Diagnosis of Giant Cell Arteritis: Results of a Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2017, 69, 161-168.	5.6	78
93	Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Autoimmunity Reviews</i> , 2017, 16, 1-9.	5.8	140
94	Gastrointestinal aspects of vasculitides. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 185-194.	17.8	27
95	Childhood Takayasu arteritis: disease course and response to therapy. <i>Arthritis Research and Therapy</i> , 2017, 19, 255.	3.5	54
96	Variations in the clinical practice of physicians managing Takayasu arteritis: a nationwide survey. <i>Open Access Rheumatology: Research and Reviews</i> , 2017, Volume 9, 91-99.	1.6	6
97	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. <i>Journal of Medical Internet Research</i> , 2017, 19, e50.	4.3	24
98	Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 176-184.	0.8	7
99	Updates in ANCA-associated vasculitis. <i>European Journal of Rheumatology</i> , 2016, 3, 122-133.	0.6	125
100	Patient-driven online survey on the clinical manifestations and diagnostic delay of granulomatosis with polyangiitis. <i>Joint Bone Spine</i> , 2016, 83, 599-600.	1.6	4
101	Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1059-1067.	3.0	16
102	Editorial: Classifying Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitides According to ANCA Type or Phenotypic Diagnosis: Salt or Pepper?. <i>Arthritis and Rheumatology</i> , 2016, 68, 2837-2840.	5.6	15
103	Letter by de Boysson and Pagnoux Regarding Article, "Diagnostic Yield and Safety of Brain Biopsy for Suspected Primary Central Nervous System Angiitis" Stroke, 2016, 47, e256.	2.0	7
104	Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis. <i>Arthritis and Rheumatology</i> , 2016, 68, 690-701.	5.6	101
105	Severe Intracranial Involvement in Giant Cell Arteritis: 5 Cases and Literature Review. <i>Journal of Rheumatology</i> , 2016, 43, 648-656.	2.0	51
106	Pharmacological approaches to CNS vasculitis: where are we at now?. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 109-116.	3.1	8
107	A small n sequential multiple assignment randomized trial design for use in rare disease research. <i>Contemporary Clinical Trials</i> , 2016, 46, 48-51.	1.8	31
108	CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides. <i>Journal of Rheumatology</i> , 2016, 43, 97-120.	2.0	66

#	ARTICLE	IF	CITATIONS
109	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 475-482.	3.4	109
110	Perinuclear antineutrophil cytoplasmic antibody-associated vasculitis in an elderly woman. <i>Canadian Family Physician</i> , 2016, 62, 635-7.	0.4	0
111	Reply to: Importance of immunisation of elderly subjects before immunosuppressive treatment. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S21.	0.8	26
112	Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: impact on global disability and health-related quality of life. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S54-9.	0.8	5
113	Do vaccinations affect the clinical course of systemic necrotising vasculitis? A prospective observational web-based study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S89-92.	0.8	8
114	Tracheobronchial Stenoses in Granulomatosis With Polyangiitis (Wegener's). <i>Medicine (United States)</i> , 2016, 95, 1053-1058.	1.0	53
115	Polyarteritis nodosa "Challenges and options in management. <i>Indian Journal of Rheumatology</i> , 2015, 10, S64-S71.	0.4	1
116	Ear, nose, and throat involvement in eosinophilic granulomatosis with polyangiitis. <i>Advances in Cellular and Molecular Otolaryngology</i> , 2015, 3, 27181.	0.4	5
117	Vasculitis research: Don't slow down and plan for a life-time commitment. <i>Presse Medicale</i> , 2015, 44, e221-e222.	1.9	0
118	Eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): where are we now?. <i>European Respiratory Journal</i> , 2015, 46, 1255-1258.	6.7	11
119	CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody (ANCA)-Associated Vasculitides "Executive Summary. <i>Canadian Journal of Kidney Health and Disease</i> , 2015, 2, 78.	1.1	12
120	Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixty-Five Years or Older: Results of a Multicenter, Open-Label, Randomized Controlled Trial of Corticosteroid and Cyclophosphamide-Based Induction Therapy. <i>Arthritis and Rheumatology</i> , 2015, 67, 1117-1127.	5.6	150
121	Treatment of granulomatosis with polyangiitis (Wegener's). <i>Expert Review of Clinical Immunology</i> , 2015, 11, 339-348.	3.0	18
122	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>European Journal of Internal Medicine</i> , 2015, 26, 545-553.	2.2	371
123	Brief Report: Childhood-Onset Systemic Necrotizing Vasculitides: Long-Term Data From the French Vasculitis Study Group Registry. <i>Arthritis and Rheumatology</i> , 2015, 67, 1959-1965.	5.6	47
124	Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , 2015, 54, 1351-1359.	1.9	52
125	Development of Canadian Recommendations for the Management of ANCA-Associated Vasculitides: Results of the National Needs Assessment Questionnaire. <i>Open Rheumatology Journal</i> , 2015, 9, 16-20.	0.2	7
126	The Role of Biological Agents in the Management of Large Vessel Vasculitis (LVV): A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e115026.	2.5	31



#	ARTICLE	IF	CITATIONS
127	Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. <i>Autoimmunity Reviews</i> , 2014, 13, 197-205.	5.8	77
128	Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: A systematic review and network meta-analysis. <i>Joint Bone Spine</i> , 2014, 81, 337-341.	1.6	25
129	Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2014, 371, 1771-1780.	27.0	842
130	Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: A retrospective multicenter study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 681-688.	3.4	15
131	Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churgâ€Strauss syndrome) enrolled in two prospective trials. <i>Journal of Autoimmunity</i> , 2013, 43, 60-69.	6.5	168
132	Eosinophilic granulomatosis with polyangiitis (Churgâ€Strauss): Clinical characteristics and longâ€term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. <i>Arthritis and Rheumatism</i> , 2013, 65, 270-281.	6.7	670
133	L38. How to treat primary vasculitis of the central nervous system. <i>Presse Medicale</i> , 2013, 42, 605-607.	1.9	3
134	Fertility and pregnancy in vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013, 27, 79-94.	3.3	36
135	Vasculitis of the upper airways. <i>Swiss Medical Weekly</i> , 2012, 142, w13541.	1.6	24
136	CNS Involvement in Acute Posterior Multifocal Placoid Pigment Epitheliopathy. <i>Canadian Journal of Neurological Sciences</i> , 2011, 38, 526-528.	0.5	11
137	Encrusting Cystitis Due to <i>Corynebacterium urealyticum</i> in a Patient with ANCA-Associated Vasculitis: Case Report and Review of the Literature. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 297-300.	3.4	18
138	Pregnancies in systemic necrotizing vasculitides: report on 12 women and their 20 pregnancies. <i>Rheumatology</i> , 2011, 50, 953-961.	1.9	62
139	Wegenerâ€™s Granulomatosis Strictly and Persistently Localized to One Organ Is Rare: Assessment of 16 Patients from the French Vasculitis Study Group Database. <i>Journal of Rheumatology</i> , 2011, 38, 475-478.	2.0	36
140	The Five-Factor Score Revisited. <i>Medicine (United States)</i> , 2011, 90, 19-27.	1.0	716
141	Churgâ€Strauss syndrome: evidence for disease subtypes?. <i>Current Opinion in Rheumatology</i> , 2010, 22, 21-28.	4.3	103
142	Remittent non-destructive polysynovitis in P-ANCA-positive vasculitis patients with anti-CCP antibodies. <i>Joint Bone Spine</i> , 2010, 77, 604-607.	1.6	9
143	Clinical features and outcomes in 348 patients with polyarteritis nodosa: A systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database. <i>Arthritis and Rheumatism</i> , 2010, 62, 616-626.	6.7	483
144	Treatment of polyarteritis nodosa and microscopic polyangiitis without poorâ€prognosis factors: A prospective randomized study of one hundred twentyâ€four patients. <i>Arthritis and Rheumatism</i> , 2010, 62, 1186-1197.	6.7	179

#	ARTICLE	IF	CITATIONS
145	Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2381.	7.4	524
146	Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission. <i>Rheumatology</i> , 2010, 49, 2181-2190.	1.9	66
147	Extraocular manifestations of birdshot chorioretinopathy in 118 French patients. <i>Presse Medicale</i> , 2010, 39, e97-e102.	1.9	21
148	Churg-Strauss syndrome: evolving concepts. <i>Discovery Medicine</i> , 2010, 9, 243-52.	0.5	29
149	Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: Results of a multicenter, prospective, open-label study of twenty-two patients. <i>Arthritis and Rheumatism</i> , 2008, 58, 308-317.	6.7	163
150	Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: Comparison of two independent cohorts. <i>Arthritis and Rheumatism</i> , 2008, 58, 2908-2918.	6.7	231
151	Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2008, 359, 2790-2803.	27.0	603
152	Therapeutic Strategies for Systemic Necrotizing Vasculitides. <i>Allergology International</i> , 2007, 56, 105-111.	3.3	23
153	Churg-Strauss syndrome. <i>Current Opinion in Rheumatology</i> , 2007, 19, 25-32.	4.3	199
154	Plasma exchange for systemic lupus erythematosus. <i>Transfusion and Apheresis Science</i> , 2007, 36, 187-193.	1.0	24
155	Indication for plasma exchange for systemic necrotizing vasculitides. <i>Transfusion and Apheresis Science</i> , 2007, 36, 179-185.	1.0	16
156	Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. <i>Arthritis and Rheumatism</i> , 2007, 57, 686-693.	6.7	243
157	Atherosclerosis in ANCA-Associated Vasculitides. <i>Annals of the New York Academy of Sciences</i> , 2007, 1107, 11-21.	3.8	25
158	Cutaneous granulomatous vasculitis and extravascular granulomas. <i>Expert Review of Dermatology</i> , 2006, 1, 315-326.	0.3	4
159	Peripheral neuropathy in systemic vasculitides. <i>Current Opinion in Rheumatology</i> , 2005, 17, 41-48.	4.3	70
160	Hepatitis B Virus-Associated Polyarteritis Nodosa. <i>Medicine (United States)</i> , 2005, 84, 313-322.	1.0	371
161	Antineutrophil Cytoplasmic Antibodies and the Churg-Strauss Syndrome. <i>Annals of Internal Medicine</i> , 2005, 143, 632.	3.9	592
162	How can patient care be improved beyond medical treatment?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 337-344.	3.3	17

#	ARTICLE	IF	CITATIONS
163	Presentation and Outcome of Gastrointestinal Involvement in Systemic Necrotizing Vasculitides. <i>Medicine (United States)</i> , 2005, 84, 115-128.	1.0	332
164	Churg-Strauss Syndrome and Leukotriene-Modifying Agents. <i>Clinical Pulmonary Medicine</i> , 2004, 11, 349-354.	0.3	9
165	When Should Immunosuppressants Be Prescribed to Treat Systemic Vasculitides?. <i>Internal Medicine</i> , 2003, 42, 313-317.	0.7	35
166	Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome). , 0, , 306-306.		3